



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

## Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2015

(Rupees in Lakhs)

Particulars	Quarter Ended			Year Ended
	30-Jun-15 (Unaudited)	30-Jun-14 (Unaudited)	31-Mar-15 (Unaudited)	31-Mar-15 (Audited)
1 (a). Net Income from Sales / Services	1,256.56	1,413.84	917.69	4,739.44
(b). Other Operating Income	0.83	3.83	1.44	17.36
Total Income	1,257.39	1,417.67	919.13	4,756.80
2. Expenditure				
a) (Increase)/Decrease in Stock in Trade/WIP	(67.28)	114.26	764.74	3,849.60
b) Consumption of Raw Materials	1,210.49	1,177.47	43.82	204.58
c) Purchase of Traded Goods	0.00	0.00	0.00	216.73
d) Employee Costs	20.25	18.79	28.83	91.20
e) Depreciation	10.84	8.65	17.28	43.76
f) Other Expenditure				
(i) Manufacturing Expenses	48.10	24.76	53.76	157.28
(ii) Administration Expenses	11.64	11.40	16.22	59.65
(iii) Selling & Distribution Expenses	8.32	12.69	7.54	44.96
g) Total	1,242.36	1,368.02	932.19	4,667.76
3. Profit from Operations before Other Income, Interest and Exceptional Items	15.03	49.65	(13.06)	89.04
4. Other Income	2.84	3.00	4.90	17.41
5. Profit before Interest and Exceptional items	17.87	52.65	(8.16)	106.45
6. Interest	5.88	12.24	11.26	58.55
7. Profit after Interest but before Exceptional items	11.99	40.41	(19.42)	47.90
8. Exceptional Items	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax	11.99	40.41	(19.42)	47.90
10. Tax expense (incl deferred tax)	4.82	16.48	(10.49)	16.31
11. Net Profit / (Loss) from ordinary activities after tax	7.17	23.93	(8.93)	31.59
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	7.17	23.93	(8.93)	31.59
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	1,043.69	1,028.80	1,036.51	1,036.51
16. Earnings per share				
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	0.23	0.77	(0.29)	1.02
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	0.23	0.77	(0.29)	1.02
17. Public shareholding				
-- Number of shares	1,629,751	1,644,269	1,633,715	1,633,715
-- Percentage of shareholding	52.75	53.22	52.88	52.88
18. Promoters and promoter group shareholding**				
a) Pledged/ Encumbered				
-- Number of shares	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00

b) Non-encumbered				
-- Number of shares	<b>1,459,949</b>	1,445,431	1,455,985	1,455,985
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	<b>100.00</b>	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	<b>47.25</b>	46.78	47.12	47.12

**Notes:**

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2015
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Friday, 14 August 2015 at the Corporate Office of the Company.
4. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 30 June, 2015

Opening Balance as on	1/Apr/2015	0
Received during the quarter		1
Disposed of during the quarter		1
Closing Balance as on	30/Jun/2015	0

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Place : Mumbai**  
**Date : 14 August 2015**

**Rajesh Mehta**  
**Executive Director**